OLD Second National Bank of Aurora Sells 576 Shares of Abbott Laboratories $ABT

OLD Second National Bank of Aurora trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 2.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,021 shares of the healthcare product maker’s stock after selling 576 shares during the period. OLD Second National Bank of Aurora’s holdings in Abbott Laboratories were worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its holdings in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Apella Capital LLC raised its holdings in Abbott Laboratories by 29.3% during the 1st quarter. Apella Capital LLC now owns 8,239 shares of the healthcare product maker’s stock valued at $1,047,000 after acquiring an additional 1,868 shares during the period. Warren Street Wealth Advisors LLC raised its holdings in Abbott Laboratories by 14.4% during the 1st quarter. Warren Street Wealth Advisors LLC now owns 2,118 shares of the healthcare product maker’s stock valued at $281,000 after acquiring an additional 267 shares during the period. Naples Global Advisors LLC boosted its holdings in Abbott Laboratories by 1.5% in the 1st quarter. Naples Global Advisors LLC now owns 29,070 shares of the healthcare product maker’s stock valued at $3,856,000 after purchasing an additional 420 shares during the period. Finally, Fluent Financial LLC boosted its holdings in Abbott Laboratories by 217.1% in the 1st quarter. Fluent Financial LLC now owns 22,217 shares of the healthcare product maker’s stock valued at $2,947,000 after purchasing an additional 15,210 shares during the period. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on ABT shares. BTIG Research cut their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Evercore ISI increased their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. The Goldman Sachs Group increased their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Leerink Partners began coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $145.39.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Trading Down 0.3%

NYSE ABT opened at $133.05 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The firm has a market capitalization of $231.56 billion, a PE ratio of 16.67, a P/E/G ratio of 2.53 and a beta of 0.69. The stock’s 50 day moving average is $131.78 and its 200 day moving average is $131.28.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter last year, the company earned $1.14 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.